A Prospective Cohort of Patients With Cervical/Intracranial Arteries Stenosis in China
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age40-80
SponsorThe First Hospital of Jilin University
About this trial
The aim of this study is to establish a prospective cohort of patients with cervical/intracranial arteries stenosis in China.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age ≥ 40 and ≤ 80 years;
Ultrasound or imaging examinations indicating cervical artery stenosis and/or intracranial artery stenosis (including mild, moderate, severe stenosis, or occlusion);
Willing to participate and signing the informed consent form.
Disqualifiers
Patients with stroke occurring within the past year;
Patients with severe systemic diseases, such as respiratory failure, renal failure, gastrointestinal bleeding, coagulation disorders, malignancies, etc.;
Patients with a life expectancy of less than one year or those who are unable to complete the study for other reasons.
Trial population
Patients who were diagnosed with cervical artery stenosis and/or intracranial artery stenosis.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
No intervention
Other interventionno intervention
Treatment groups
60,000 Participants
are divided into 1 treatment groupGroup A: Patients with cervical/intracranial arteries stenosis1 intervention
Trial outcomes
Primary outcomes
1
Incidence of stroke
Incidence of stroke events including ischemic stroke, transient ischaemic attack and haemorrhagic stroke.
Time frame
One yearSecondary outcomes
1
Changes in the stenosis rate of cervical and intracranial arteries
The changes in the stenosis rate of cervical and intracranial arteries.
Time frame
One year2
Incidence of new clinical vascular events
Incidence of new clinical vascular events (ischemic stroke/ hemorrhagic stroke/ transient ischemic stroke/ myocardial infarction/ vascular death) as a cluster and evaluated individually. Vascular death was defined as death due to stroke (ischemic or hemorrhagic), systemic hemorrhage, myocardial infarction, congestive heart failure, pulmonary embolism, sudden death, or arrhythmia.
Time frame
One yearSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: